AveXis (NASDAQ:AVXS) received a $110.00 price objective from research analysts at Canaccord Genuity in a report released on Friday, January 5th. The firm presently has a “hold” rating on the stock. Canaccord Genuity’s price target suggests a potential downside of 6.38% from the company’s current price.
Several other equities analysts have also commented on AVXS. Chardan Capital reissued a “buy” rating and issued a $135.00 target price on shares of AveXis in a report on Friday, January 5th. Citigroup lifted their price target on shares of AveXis from $100.00 to $116.00 and gave the company a “buy” rating in a report on Monday, October 2nd. Morgan Stanley set a $120.00 price target on shares of AveXis and gave the company a “buy” rating in a report on Friday, January 5th. UBS Group set a $122.00 target price on shares of AveXis and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $123.00 target price on shares of AveXis in a report on Saturday, September 30th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $111.67.
Shares of AveXis (NASDAQ:AVXS) opened at $117.50 on Friday. AveXis has a 12 month low of $50.56 and a 12 month high of $119.00. The stock has a market cap of $3,720.14, a PE ratio of -21.06 and a beta of 2.46.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same period last year, the business posted ($0.87) EPS. equities research analysts forecast that AveXis will post -6.23 earnings per share for the current year.
In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at $661,360. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $109.75, for a total transaction of $1,646,250.00. Following the sale, the insider now directly owns 1,808,386 shares in the company, valued at $198,470,363.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,340 shares of company stock valued at $5,318,845. 18.60% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank lifted its holdings in shares of AveXis by 19.6% in the third quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after buying an additional 523 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of AveXis by 2.9% in the second quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after buying an additional 598 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of AveXis by 6.4% in the second quarter. ProShare Advisors LLC now owns 16,427 shares of the company’s stock worth $1,350,000 after buying an additional 985 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of AveXis by 28.2% in the second quarter. SG Americas Securities LLC now owns 5,111 shares of the company’s stock worth $420,000 after buying an additional 1,124 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of AveXis in the third quarter worth about $116,000. 92.88% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/avexis-avxs-given-a-110-00-price-target-at-canaccord-genuity-2.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.